Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Shahjee, Hanief M ^a   Koch, Kristopher R ^a   Guo, Li ^a   Zhang, Chen Ou ^a   Keay, Susan K ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROLIFERATIVE FACTOR; BETA ACTIN; BETA CATENIN; CYTOSKELETON PROTEIN; DOUBLE STRANDED RNA; FRIZZLED PROTEIN; GELATINASE A; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOPEPTIDE; MESSENGER RNA; PROTEIN CKAP4; PROTEIN KINASE B; PROTEIN P53; SERINE; SMALL INTERFERING RNA; THREONINE; THYMIDINE; TYROSINE; UNCLASSIFIED DRUG; WNT PROTEIN; ANTIPROLIFERATIVE FACTOR APF, HUMAN; CKAP4 PROTEIN, HUMAN; GLYCOPROTEIN; MEMBRANE PROTEIN;

ARTICLE; BLADDER CARCINOMA; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; ELECTROPORATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BLADDER TUMOR; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE;

BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 78651408943     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-160     Document Type: Article

References (46)

1. Cancer statistics, 2007. A Jemal R Siegel E Ward T Murray J Xu MJ Thun, CA Cancer J Clin 2007 57 43 66 10.3322/canjclin.57.1.43 17237035
2. Bladder cancer. DS Kaufman WU Shipley AS Feldman, Lancet 2009 74 239 249 10.1016/S0140-6736(09)60491-8
3. Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. G Sonpavde CN Sternberg, BJU Int 2008 102 1354 1360 10.1111/j.1464-410X.2008.07982.x 19035904
4. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. PK Lipponen MJ Eskelinen, J Cancer Res Clin Oncol 1995 121 303 308 10.1007/BF01209598 7768969
5. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. KN Syrigos T Krausz J Waxman H Pandha G Rowlinson-Busza J Verne AA Epenetos M Pignatelli, Int J Cancer 1995 64 367 370 10.1002/ijc.2910640603 8550236
6. Loss of human E-cadherin (ECD) correlated with invasiveness of transitional cell cancer in renal pelvis, ureter and urinary bladder. S Wakatsuki R Watanabe K Saito T Saito A Katagiri S Sato Y Tomita, Cancer Lett 1996 103 11 17 10.1016/0304-3835(96)04194-8 8616803
7. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. F Erdemir F Ozcan I Kilicaslan BS Parlaktas N Uluocak O Gokce, Int Urol Nephrol 2007 39 1031 1037 10.1007/s11255-006-9159-5 17340210
8. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. T Otto W Birchmeier U Schmidt A Hinke J Schipper H Rübben A Raz, Cancer Res 1994 54 3120 3123 8205527
9. p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. JW Slaton WF Benedict CP Dinney, Urology 2001 57 852 859 10.1016/S0090-4295(01)00968-2 11337281
10. p53 and chemosensitivity in bladder cancer. H Nishiyama J Watanabe O Ogawa, Int J Clin Oncol 2008 13 282 286 10.1007/s10147-008-0815-x 18704627
11. WAF1/CIP1 expression on tumor progression in bladder cancer. JP Stein DA Ginsberg GD Grossfeld SJ Chatterjee D Esrig MG Dickinson S Groshen CR Taylor PA Jones DG Skinner RJ Cote, J Natl Cancer Instit 1998 90 1072 1079 10.1093/jnci/90.14.1072
12. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. VB Thøgersen BS Sørensen SS Poulsen TF Orntoft H Wolf E Nexo, Cancer Res 2001 61 6227 6233 11507076
13. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. B Schäfer A Gschwind A Ullrich, Oncogene 2004 23 991 999 14647423
14. HB-EGF is a potent inducer of tumor growth and angiogenesis. PP Ongusaha JC Kwak AJ Zwible S Macip S Higashiyama N Taniguchi L Fang SW Lee, Cancer Res 2004 64 5283 5290 10.1158/0008-5472.CAN-04-0925 15289334
15. A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. RM Adam T Danciu DL McLellan JG Borer J Lin D Zurakowski MH Weinstein PH Rajjayabun JK Mellon MR Freeman, Cancer Res 2003 63 484 490 12543806
16. 3H-thymidine incorporation by human bladder epithelial cells following exposure to urine from interstitial cystitis patients. S Keay C-O Zhang M Hise AL Trifillis JR Hebel SC Jacobs JW Warren, J Urol 1996 156 2073 2078 10.1016/S0022-5347(01)65438-7 8911393
17. Bladder epithelial cells from interstitial cystitis patients produce an inhibitor of HB-EGF production. S Keay M Kleinberg C-O Zhang MK Hise JW Warren, J Urol 2000 164 2112 2118 10.1016/S0022-5347(05)66980-7 11061938
18. Antiproliferative activity is present in bladder but not renal pelvic urine from interstitial cystitis patients. S Keay JW Warren C-O Zhang LM Tu DA Gordon KE Whitmore, J Urol 1999 162 1487 1489 10.1016/S0022-5347(05)68345-0 10492242
19. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. SK Keay Z Szekely TP Conrads TD Veenstra JJ Barchi Jr CO Zhang KR Koch CJ Michejda, Proc Natl Acad Sci USA 2004 101 11803 11808 10.1073/pnas.0404509101 15282374
20. Decreased in vitro proliferation of bladder epithelial cells from patients with interstitial cystitis. S Keay C-O Zhang JL Shoenfelt TC Chai, Urology 2003 61 1278 1284 10.1016/S0090-4295(03)00005-0 12809929
21. Changes in human bladder cell gene expression associated with interstitial cystitis or antiproliferative factor treatment. S Keay F Seillier-Moiseiwitsch C-O Zhang TC Chai J Zhang, Physiol Genomics 2003 14 107 115 12847144
22. p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells. J Kim SK Keay JD Dimitrakov MR Freeman, FEBS Lett 2007 581 3795 3799 10.1016/j.febslet.2007.06.058 17628545
23. Regulation of tight junction proteins and bladder epithelial paracellular permeability by an antiproliferative factor from patients with interstitial cystitis. C-O Zhang JY Wang KR Koch S Keay, J Urol 2005 174 2382 2387 10.1097/01.ju.0000180417.11976.99 16280852
24. Clinical features and spectrum of light microscopic changes in interstitial cystitis. SL Johansson M Fall, J Urol 1990 143 1118 1124 2342171
25. Critical Notes: Respective immune pathogenesis of interstitial cystitis (article in German). D Skoluda K Wegner EM Lemmel, Urologe A 1974 13 15 23 4596210
26. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the Interstitial Cystitis Database Study Group. JE Tomaszewski JR Landis V Russack TM Williams LP Wang C Hardy C Brensinger YL Matthews ST Abele JW Kusek LM Nyberg Interstitial Cystitis Database Study Group, Urology 2001 57 67 81 10.1016/S0090-4295(01)01166-9 11378053
27. CKAP4 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. TP Conrads GM Tocci BL Hood CO Zhang L Guo KR Koch CJ Michejda TD Veenstra SK Keay, J Biol Chem 2006 281 37836 37843 10.1074/jbc.M604581200 17030514
28. Characterization of a novel 63 kDa membrane protein. Implications for the organization of the ER-to-Golgi pathway. A Schweizer M Ericsson T Bächi G Griffiths HP Hauri, J Cell Sci 1993 104 671 683 8314869
29. Palmitoylation of cytoskeleton associated protein 4 by DHHC2 regulates antiproliferative factor-mediated signaling. SL Planey SK Keay C-O Zhang DA Zacharias, Mol Biol Cell 2009 20 1454 1463 10.1091/mbc.E08-08-0849 19144824
30. Wnt signaling through canonical and non-canonical pathways: recent progress. R Widelitz, Growth Factors 2005 23 111 116 10.1080/08977190500125746 16019432
31. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. X Zi Y Guo AR Simoneau C Hope J Xie RF Holcombe BH Hoang, Cancer Res 2005 65 9762 9770 10.1158/0008-5472.CAN-05-0103 16266997
32. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. B Wu SP Crampton CC Hughes, Immunity 2007 26 227 239 10.1016/j.immuni.2006.12.007 17306568
33. Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. S Roelle R Grosse A Aigner HW Krell F Czubayko T Gudermann, J Biol Chem 2003 278 47307 47318 10.1074/jbc.M304377200 12963732
34. Matrix metalloproteinases and bladder cancer. H Kanayama, J Med Invest 2001 48 31 43 11286015
35. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. S Gerhards K Jung F Koenig D Daniltchenko S Hauptmann D Schnorr SA Loening, Urology 2001 57 675 679 10.1016/S0090-4295(00)01087-6 11306379
36. Increased incidence of matrix metalloproteinases in urine of cancer patients. MA Moses D Wiederschain KR Loughlin D Zurakowski CC Lamb MR Freeman, Cancer Res 1998 58 1395 1399 9537238
37. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. AS Papathoma C Petraki A Grigorakis H Papakonstantinou V Karavana S Stefanakis F Sotsiou A Pintzas, Anticancer Res 2000 20 2009 2013 10928143
38. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. H Yagi F Yotsumoto S Miyamoto, Mol Cancer Ther 2008 7 3441 10.1158/1535-7163.MCT-08-0417 18852147
39. Winding through the WNT pathway during cellular development and demise. F Li ZZ Chong K Maiese, Histol Histopathol 2006 21 103 124 16267791
40. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. X Wu T Obata Q Khan RA Highshaw R DeVere White C Sweeney, BJU Int 2004 93 143 50 10.1111/j.1464-410X.2004.04574.x 14678387
41. The Akt/PKB pathway: molecular target for cancer drug discovery. JQ Cheng CW Lindsley GZ Cheng H Yang SV Nicosia, Oncogene 2005 24 7482 7492 10.1038/sj.onc.1209088 16288295
42. Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. QM Wang CJ Fiol AA DePaoli-Roach PJ Roach, J Biol Chem 1994 269 14566 14574 7514173
43. Glycogen synthase kinase-3beta is tyrosine-phosphorylated by MEK1 in human skin fibroblasts. F Takahashi-Yanaga F Shiraishi M Hirata Y Miwa S Morimoto T Sasaguri, Biochem Biophys Res Commun 2004 316 411 415 10.1016/j.bbrc.2004.02.061 15020233
44. Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. T Hagen A Vidal-Puig, Biochem Biophys Res Commun 2002 294 324 328 10.1016/S0006-291X(02)00485-0 12051714
45. Metalloproteinases and cancer invasion. WG Stetler-Stevenson, Semin Cancer Biol 1990 1 99 106 2103492
46. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl) maleimides as glycogen synthase kinase 3 beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. IN Gaisina F Gallier AV Ougolkov KH Kim T Kurome S Guo D Holzle DN Luchini SY Blond DD Billadeau AP Kozikowski, J Med Chem 2009 52 1853 1863 10.1021/jm801317h 19338355